Armata PharmaceuticalsARMP
Market Cap: $84.3M
About: Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Employees: 75
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.04% less ownership
Funds ownership: 3.93% [Q1] → 3.88% (-0.04%) [Q2]
4% less funds holding
Funds holding: 24 [Q1] → 23 (-1) [Q2]
35% less capital invested
Capital invested by funds: $5.94M [Q1] → $3.86M (-$2.07M) [Q2]
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $156K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 200%upside $7 | Buy Reiterated | 15 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 200%upside $7 | Buy Reiterated | 11 Jul 2024 |
Financial journalist opinion
Based on 4 articles about ARMP published over the past 30 days